United States Army

Ivy Mass exercises NGC2 at division scale

In less than one year the Army advanced its novel approach to modernizing command and control capabilities from ...
Yahoo Finance

Will Nvidia-Backed BioHive-2 and Big Pharma Alliances Redefine Recursion Pharmaceuticals' (RXRX) Narrative

Earlier in January, Recursion Pharmaceuticals updated investors at the JP Morgan Healthcare Conference on its AI-powered drug discovery platform, clinical programs, and collaborations with partners ...
Hosted on MSN

Roche Exercises Option with Recursion Pharmaceuticals

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Recursion ...
Psychology Today

Steven Pinker on the Recursive Loop That Made Us Human

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...
Mashable

25+ of the best Stanford University courses you can take online for free

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. TL;DR: Online courses from ...
Yahoo Finance

Recursion Pharmaceuticals: Q2 Earnings Snapshot

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
bernama

Recursion: Non-antibiotic Treatment For Recurrent C. diff Infection Enters Phase 2 Trial

KUALA LUMPUR, Oct 23 (Bernama) -- Recursion, a clinical stage TechBio company, announced the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral ...
PharmiWeb

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides ...

SALT LAKE CITY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient ...
Nasdaq

Recursion: REC-994 Meets Primary Endpoint Of Safety, Tolerability In 12-month Phase 2 Study

(RTTNews) - Recursion (RXRX) reported top-line results of the SYCAMORE trial, a 12-month Phase 2 randomized double-blind, placebo-controlled, safety, tolerability and exploratory efficacy study for ...
TMCnet

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of ...

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top-line results of ...
Nasdaq

Recursion (RXRX) to Report Q2 Earnings: What's in the Cards?

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...